Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie B Laederich

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Pediatrics|July 6, 2010
Achondroplasia: pathogenesis and implications for future treatmentMelanie B Laederich, William A Horton
Expert Reviews in Molecular Medicine|May 8, 2012
FGFR3 targeting strategies for achondroplasiaMelanie B Laederich, William A Horton
Journal of Cellular Biochemistry|June 22, 2010
FGFs in endochondral skeletal developmentCatherine R Degnin, Melanie B Laederich, William A Horton
Molecular Biology of the Cell|August 26, 2011
Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3Catherine R Degnin, Melanie B Laederich, William A Horton
The Journal of Biological Chemistry|April 14, 2011
Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulationMelanie B Laederich, Catherine R Degnin, Gregory P Lunstrum, et al.
The Journal of Biological Chemistry|September 4, 2004
The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinasesMelanie B Laederich, Melanie Funes-Duran, Lily Yen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2015
Multimodular biosensors reveal a novel platform for activation of G proteins by growth factor receptorsKrishna K Midde, Nicolas Aznar, Melanie B Laederich, et al.
Cellular Signalling|May 20, 2008
Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasiaChangsheng Guo, Catherine R Degnin, Melanie B Laederich, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Pediatrics|July 6, 2010
Achondroplasia: pathogenesis and implications for future treatmentMelanie B Laederich, William A Horton
Expert Reviews in Molecular Medicine|May 8, 2012
FGFR3 targeting strategies for achondroplasiaMelanie B Laederich, William A Horton
Journal of Cellular Biochemistry|June 22, 2010
FGFs in endochondral skeletal developmentCatherine R Degnin, Melanie B Laederich, William A Horton
Molecular Biology of the Cell|August 26, 2011
Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3Catherine R Degnin, Melanie B Laederich, William A Horton
The Journal of Biological Chemistry|April 14, 2011
Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulationMelanie B Laederich, Catherine R Degnin, Gregory P Lunstrum, et al.
The Journal of Biological Chemistry|September 4, 2004
The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinasesMelanie B Laederich, Melanie Funes-Duran, Lily Yen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2015
Multimodular biosensors reveal a novel platform for activation of G proteins by growth factor receptorsKrishna K Midde, Nicolas Aznar, Melanie B Laederich, et al.
Cellular Signalling|May 20, 2008
Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasiaChangsheng Guo, Catherine R Degnin, Melanie B Laederich, et al.
Pageof 1